Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1744-8603
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis ; volume:16 ; number:1 ; day:14 ; month:10 ; year:2020 ; pages:1-12 ; date:12.2020
Globalization and health ; 16, Heft 1 (14.10.2020), 1-12, 12.2020
- Creator
-
Son, Kyung-Bok
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12992-020-00633-9
- URN
-
urn:nbn:de:101:1-2020112913563861570224
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Son, Kyung-Bok
- SpringerLink (Online service)
Other Objects (12)
Medicines and the media: news reports of medicines recommended for government reimbursement in Australia
Impact of delisting OTC medicines from reimbursement list
Approval, reimbursement and pricing of high-cost cancer medicines in Australia
Patient organisations and the reimbursement process for medicines: an exploratory study in eight European countries
Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List
Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey
Network medicines™
Reimbursement categories as a way of allocating measures and monitoring expenditures on medicines
In development new medicines for women
Regulatory roadmap for nanotechnology based medicines
Translational medicines “Ecosystem”
The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy
Medicines and the media: news reports of medicines recommended for government reimbursement in Australia
Impact of delisting OTC medicines from reimbursement list
Approval, reimbursement and pricing of high-cost cancer medicines in Australia
Patient organisations and the reimbursement process for medicines: an exploratory study in eight European countries
Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List
Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey
Network medicines™
Reimbursement categories as a way of allocating measures and monitoring expenditures on medicines
In development new medicines for women
Regulatory roadmap for nanotechnology based medicines
Translational medicines “Ecosystem”
The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy
Medicines and the media: news reports of medicines recommended for government reimbursement in Australia
Impact of delisting OTC medicines from reimbursement list
Approval, reimbursement and pricing of high-cost cancer medicines in Australia
Patient organisations and the reimbursement process for medicines: an exploratory study in eight European countries
Evidence for the effectiveness of anti-hypertensive medicines included on the Chinese National Reimbursement Drug List
Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey
Network medicines™
Reimbursement categories as a way of allocating measures and monitoring expenditures on medicines
In development new medicines for women
Regulatory roadmap for nanotechnology based medicines
Translational medicines “Ecosystem”